An Open-Label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma

Trial Profile

An Open-Label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs APR 246 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Aprea
  • Most Recent Events

    • 18 Sep 2012 Results have been published in the Journal of Clinical Oncology according to an Aprea media release. Results were also summarised in the media release.
    • 24 Nov 2010 Status changed from recruiting to completed, as reported in ClincialTrials.gov.
    • 28 May 2010 Trial design will be discussed at the annual American Society of Clinical Oncology (ASCO) conference, as reported in an Aprea AB media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top